These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 30442536

  • 21. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [Abstract] [Full Text] [Related]

  • 22. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Valgimigli M, Campo G, Malagutti P, Anselmi M, Bolognese L, Ribichini F, Boccuzzi G, de Cesare N, Rodriguez AE, Russo F, Moreno R, Biondi-Zoccai G, Penzo C, Díaz Fernández JF, Parrinello G, Ferrari R.
    JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629
    [Abstract] [Full Text] [Related]

  • 23. Impact of stent generation on 2-year clinical outcomes in ST-segment elevation myocardial infarction patients with multivessel disease who underwent culprit-only or multivessel percutaneous coronary intervention.
    Kim YH, Her AY, Jeong MH, Kim BK, Hong SJ, Kim JS, Ko YG, Choi D, Hong MK, Jang Y.
    Catheter Cardiovasc Interv; 2020 Feb; 95(2):E40-E55. PubMed ID: 31423723
    [Abstract] [Full Text] [Related]

  • 24. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial.
    Konigstein M, Ben-Yehuda O, Smits PC, Love MP, Banai S, Perlman GY, Golomb M, Ozan MO, Liu M, Leon MB, Stone GW, Kandzari DE.
    JACC Cardiovasc Interv; 2018 Dec 24; 11(24):2467-2476. PubMed ID: 30573057
    [Abstract] [Full Text] [Related]

  • 25. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
    Zocca P, Kok MM, Tandjung K, Danse PW, Jessurun GAJ, Hautvast RWM, van Houwelingen KG, Stoel MG, Schramm AR, Tjon Joe Gin RM, de Man FHAF, Hartmann M, Louwerenburg JHW, Linssen GCM, Löwik MM, Doggen CJM, von Birgelen C.
    JACC Cardiovasc Interv; 2018 Mar 12; 11(5):462-469. PubMed ID: 29519378
    [Abstract] [Full Text] [Related]

  • 26. Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: Baseline OCT and 30-day clinical outcomes - A FANTOM STEMI pilot study.
    Koltowski L, Tomaniak M, Ochijewicz D, Maksym J, Roleder T, Zaleska M, Proniewska K, Opolski G, Kochman J.
    Catheter Cardiovasc Interv; 2020 Jul 12; 96(1):E1-E7. PubMed ID: 31343827
    [Abstract] [Full Text] [Related]

  • 27. Comparison of a Simple Angiographic Approach With a Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Score-Based Approach for Left Main Coronary Artery Stenting: A Pooled Analysis of Serial PRECOMBAT (Premier of Randomized Comparison of Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease) Studies.
    Lee PH, Lee JY, Lee CW, Kim SO, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Park SJ.
    Circ Cardiovasc Interv; 2018 Jan 12; 11(1):e005374. PubMed ID: 29311287
    [Abstract] [Full Text] [Related]

  • 28. Long-term clinical impact of polymer-free sirolimus-eluting stents in unselected patients.
    Sinha N, Rai H, Cassese S, Kumar S, Kapoor A, Kastrati A.
    Coron Artery Dis; 2016 Aug 12; 27(5):385-90. PubMed ID: 27124380
    [Abstract] [Full Text] [Related]

  • 29. Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.
    Jensen LO, Thayssen P, Maeng M, Ravkilde J, Krusell LR, Raungaard B, Junker A, Terkelsen CJ, Veien KT, Villadsen AB, Kaltoft A, Tilsted HH, Hansen KN, Aaroe J, Kristensen SD, Hansen HS, Jensen SE, Madsen M, Bøtker HE, Berencsi K, Lassen JF, Christiansen EH.
    Circ Cardiovasc Interv; 2016 Jul 12; 9(7):. PubMed ID: 27412869
    [Abstract] [Full Text] [Related]

  • 30. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease.
    Kufner S, Joner M, Thannheimer A, Hoppmann P, Ibrahim T, Mayer K, Cassese S, Laugwitz KL, Schunkert H, Kastrati A, Byrne RA, ISAR-TEST 4 (Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents) Investigators.
    Circulation; 2019 Jan 15; 139(3):325-333. PubMed ID: 30586724
    [Abstract] [Full Text] [Related]

  • 31. One-year outcome from an all-comers population of patients with ST-segment elevation myocardial infarction treated with biolimus-eluting stent with biodegradable polymer.
    Tomai F, De Luca L, Altamura L, Versaci F, Pennacchi M, Proietti I, Ghini AS, Corvo P, De Persio G, Petrolini A, Tommasino A, Sardella G.
    Catheter Cardiovasc Interv; 2015 Feb 15; 85(3):352-8. PubMed ID: 25115927
    [Abstract] [Full Text] [Related]

  • 32. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
    Iglesias JF, Muller O, Heg D, Roffi M, Kurz DJ, Moarof I, Weilenmann D, Kaiser C, Tapponnier M, Stortecky S, Losdat S, Eeckhout E, Valgimigli M, Odutayo A, Zwahlen M, Jüni P, Windecker S, Pilgrim T.
    Lancet; 2019 Oct 05; 394(10205):1243-1253. PubMed ID: 31488372
    [Abstract] [Full Text] [Related]

  • 33. Clinical outcomes of an ultrathin-strut sirolimus-eluting stent in all-comers population: Thailand Orsiro registry.
    Suwannasom P, Athiksakul S, Thonghong T, Lertsuwunseri V, Chaipromprasit J, Srimahachota S, Udayachalerm W, Kuanprasert S, Buddhari W.
    BMC Cardiovasc Disord; 2021 Oct 16; 21(1):501. PubMed ID: 34656088
    [Abstract] [Full Text] [Related]

  • 34. Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials.
    Xu K, Fu G, Xu B, Zhou Y, Su X, Liu H, Zhang Z, Yu B, Wang X, Han Y, NeoVas OPC Investigators.
    Catheter Cardiovasc Interv; 2019 Feb 15; 93(S1):832-838. PubMed ID: 30888736
    [Abstract] [Full Text] [Related]

  • 35. Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.
    Kervinen K, Niemelä M, Romppanen H, Erglis A, Kumsars I, Maeng M, Holm NR, Lassen JF, Gunnes P, Stavnes S, Jensen JS, Galløe A, Narbute I, Sondore D, Christiansen EH, Ravkilde J, Steigen TK, Mannsverk J, Thayssen P, Hansen KN, Helqvist S, Vikman S, Wiseth R, Aarøe J, Jokelainen J, Thuesen L, Nordic PCI Study Group.
    JACC Cardiovasc Interv; 2013 Nov 15; 6(11):1160-5. PubMed ID: 24262616
    [Abstract] [Full Text] [Related]

  • 36. The BIOFLOW-III Italian Satellite Registry: 18-month results of the Orsiro stent in an all-comer high-risk population.
    Bartorelli AL, Versaci F, Briguori C, Tomai F, Aprigliano G, Poli A, Vigna C, Marinucci L, My L, Masi F, Turturo M.
    J Cardiovasc Med (Hagerstown); 2019 Jul 15; 20(7):464-470. PubMed ID: 30994511
    [Abstract] [Full Text] [Related]

  • 37. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial.
    Kufner S, Sorges J, Mehilli J, Cassese S, Repp J, Wiebe J, Lohaus R, Lahmann A, Rheude T, Ibrahim T, Massberg S, Laugwitz KL, Kastrati A, Byrne RA, ISAR-TEST-5 Investigators.
    JACC Cardiovasc Interv; 2016 Apr 25; 9(8):784-792. PubMed ID: 27017366
    [Abstract] [Full Text] [Related]

  • 38. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
    Roguin A, Kandzari DE, Marcusohn E, Koolen JJ, Doros G, Massaro JM, Garcia-Garcia HM, Bennett J, Gharib EG, Cutlip DE, Waksman R.
    Circ Cardiovasc Interv; 2018 Oct 25; 11(10):e007331. PubMed ID: 30354631
    [Abstract] [Full Text] [Related]

  • 39. Randomized comparison of novel biodegradable polymer and durable polymer-coated cobalt-chromium sirolimus-eluting stents: Three-Year Outcomes of the I-LOVE-IT 2 Trial.
    Song L, Li J, Guan C, Jing Q, Lu S, Yang L, Xu K, Yang Y, Xu B, Han Y, I-LOVE-IT 2 Investigators.
    Catheter Cardiovasc Interv; 2018 Feb 15; 91(S1):608-616. PubMed ID: 29322619
    [Abstract] [Full Text] [Related]

  • 40. Predictors of clinical outcomes after coronary implantation of bioresorbable polymer sirolimus-eluting Ultimaster stents in all-comers: A report of 1,727 cases.
    Tadano Y, Kotani JI, Kashima Y, Hachinohe D, Watanabe T, Sugie T, Kaneko U, Kobayashi K, Kanno D, Fujita T.
    Catheter Cardiovasc Interv; 2019 Jul 01; 94(1):91-97. PubMed ID: 30636371
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.